Core Viewpoint - The company, Sains Environmental Co., Ltd., has released its 2025 semi-annual report, which reflects its financial status and operational results for the first half of the year [1][6]. Company Overview - The company is listed under the stock code 688480 and is referred to as Sains [1]. - The semi-annual report is not audited [2]. Financial Data - The company raised a total of RMB 454.69 million through its initial public offering, with a net amount of RMB 399.24 million after deducting underwriting and related fees [11]. - As of June 30, 2025, the company has invested RMB 321.70 million of the raised funds into relevant projects [16]. Shareholder Information - The report includes details about the top ten shareholders and their holdings, although specific data is not provided in the excerpts [2][4]. Management of Raised Funds - The company has established a special account for managing the raised funds, adhering to regulatory requirements [14]. - A total of RMB 1.05 million was earned from cash management of temporarily idle raised funds [19]. Use of Raised Funds - The company has not used idle raised funds to supplement working capital during the reporting period [18]. - As of June 30, 2025, the company has permanently supplemented working capital with RMB 50 million from the remaining raised funds [21]. Project Completion and Fund Allocation - The construction project for the environmental equipment production base was completed and reached a usable state by June 30, 2024, with a remaining balance of RMB 57.84 million expected to be used for working capital [26].

Core Viewpoint - The company has released its 2025 semi-annual report, which reflects its financial status and operational performance, ensuring compliance with relevant regulations and internal procedures [8][9]. Group 1: Company Overview - The company is identified as Xiamen Te Bao Biological Engineering Co., Ltd., with stock code 688278 [12]. - The semi-annual report is unaudited and emphasizes the importance of reading the full report for a comprehensive understanding of the company's performance [4][1]. Group 2: Financial Data - The total amount raised from the initial public offering was RMB 383.16 million, with a net amount of RMB 330.45 million after deducting issuance costs [13]. - As of June 30, 2025, the company has utilized RMB 0.304 million in the current year and a cumulative total of RMB 385.13 million from the raised funds [15]. Group 3: Fund Management - The company has established a fundraising management system to ensure the proper use and management of raised funds, adhering to legal and regulatory requirements [16]. - A tripartite supervision agreement was signed with the sponsor and the bank for the storage of raised funds, ensuring compliance with the agreement [17]. Group 4: Fund Usage and Adjustments - The company has not used idle raised funds for temporary working capital or cash management during the reporting period [20][21]. - There was an adjustment in the investment amounts for specific projects, with the protein drug production project receiving an increase from RMB 159.40 million to RMB 199.40 million [26].

Core Viewpoint - The company, Qingdao Sanbai Shuo Health Technology Co., Ltd., has disclosed its 2025 semi-annual report and related resolutions from board meetings, indicating no changes in major shareholder structure and outlining future plans for shareholder returns and governance adjustments [1][8][14]. Company Basic Information - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [5][6]. - The board of directors and the supervisory board have both approved the semi-annual report and its summary, with unanimous votes in favor [8][22]. Financial Data and Fund Management - The company raised a total of approximately RMB 680.74 million through its initial public offering, with a net amount of RMB 610.65 million after deducting issuance costs [50]. - As of June 30, 2025, the balance of the special account for raised funds was RMB 2.30 million, with an additional RMB 466 million in cash management accounts, totaling RMB 468.30 million [53]. - The company has utilized RMB 141.43 million of the raised funds for various projects, with plans to use up to RMB 500 million of temporarily idle funds for cash management [54][56]. Governance and Structural Changes - The company has decided to abolish the supervisory board, transferring its responsibilities to the audit committee of the board of directors, and has proposed amendments to its articles of association accordingly [10][23]. - A new three-year shareholder return plan for 2025-2027 has been approved, which will be submitted for shareholder meeting approval [14][26]. Upcoming Shareholder Meeting - The company plans to hold its first extraordinary general meeting of 2025 on September 9, 2025, to discuss various proposals, including the amendments to the articles of association and the shareholder return plan [18][30].

Group 1 - The company has opened a temporary special account for idle raised funds to supplement working capital, with a limit of up to RMB 200 million, for a period not exceeding 12 months [3][4][12] - The total amount raised from the non-public offering was RMB 695.58 million, with a net amount of RMB 684.93 million after deducting issuance costs [2] - The company has signed a tripartite supervision agreement with the sponsor and the bank to ensure proper management and usage of the raised funds [4][5][6] Group 2 - The company has utilized idle raised funds for cash management, with a maximum of RMB 450 million approved for investment in financial products [12][16] - The company has redeemed RMB 50 million in financial products, earning a cash management return of RMB 257,952.99, which has been fully deposited into the special account [13][16] - The company has invested RMB 30 million in a structured deposit with a projected annual yield of 1.45%, ensuring that the investment does not affect the normal operation of the fundraising projects [14][16]

Group 1 - The company has approved the termination of the "Commercial Professional Pump Industrialization Project" and plans to permanently supplement the remaining raised funds into working capital [30][38][41] - The company raised a total of RMB 517.60 million through a non-public offering of shares, with a net amount of RMB 512.10 million after deducting issuance costs [14][32] - As of June 30, 2025, the balance of the raised funds in the special account was RMB 2.78 million, and the company temporarily supplemented working capital with RMB 35 million from idle raised funds [15][19] Group 2 - The company will hold its first temporary shareholders' meeting of 2025 on September 8, 2025, to discuss the approved resolutions [46][47] - The company will conduct a half-year performance briefing on September 2, 2025, to communicate with investors and address their concerns [58][61] - The company has established a dual supply chain to ensure stable supply to the North American market, with an overseas production base set up in Thailand [38][39]

Core Viewpoint - The company has released its 2025 semi-annual report, detailing its financial performance and management of raised funds, while ensuring compliance with relevant regulations and transparency in operations [1][5][20]. Group 1: Company Overview - Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is engaged in the development and production of vaccines and biological products [2]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [2]. Group 2: Financial Data - The total amount raised from a non-public offering in June 2022 was approximately RMB 349,999.99 million, with a net amount of RMB 346,015.57 million after deducting related expenses [20]. - As of June 30, 2025, the remaining balance of raised funds was RMB 150,940.25 million, including RMB 23,025.20 million in dedicated accounts and RMB 127,915.05 million in principal-protected financial products [21][22]. Group 3: Fund Management - The company has established a dedicated fund management system, ensuring that raised funds are stored in special accounts and managed in compliance with regulations [23][24]. - The company has signed tripartite supervision agreements with banks and its sponsor to ensure the proper use of raised funds [24][25]. Group 4: Fund Utilization - In the first half of 2025, the company directly invested RMB 19,132.35 million into projects funded by the raised capital [21]. - The company has not terminated any new fundraising investment projects during the reporting period [30]. Group 5: Impairment Provisions - The company has recognized a total impairment provision of RMB 8,085.62 million for the first half of 2025, which includes credit impairment losses of RMB 5,743 million and inventory impairment losses of RMB 2,342.62 million [42][44]. - The increase in credit impairment losses is attributed to delayed payments from local disease control centers due to financial constraints [41]. Group 6: Investor Communication - The company plans to hold a semi-annual performance briefing on September 2, 2025, to address investor inquiries and provide insights into its financial results [35][36].

Group 1 - The company has completed its initial public offering (IPO) by issuing 22 million shares at a price of RMB 38.85 per share, raising a total of RMB 854.7 million, with a net amount of RMB 758.56 million after deducting fees [3][4] - The company also issued convertible bonds with a total face value of RMB 950 million, raising a net amount of RMB 939.93 million after fees [4] - As of June 30, 2025, the company has used RMB 100 million from the IPO funds to permanently supplement working capital [12] Group 2 - The company has established a management method for the raised funds to ensure compliance with regulations and protect investor rights [3][4] - The company has signed tripartite supervision agreements with banks for the management of raised funds, ensuring proper oversight [5][6] - As of June 30, 2025, the company has not used any idle IPO funds for cash management [15] Group 3 - The company has not experienced any delays in the investment projects funded by the IPO or convertible bond proceeds during the reporting period [8][9] - The actual investment amounts for the industrial robot production project and the R&D center exceeded the initial commitments, with differences funded by interest income [29] - The company has not made any changes to the investment projects or transferred funds to external parties [25] Group 4 - The company has revised its governance system to align with the latest legal and regulatory requirements [30] - The company will participate in a collective performance briefing for the new energy industry on September 3, 2025, to discuss its half-year results [32][36] - Investors can submit questions for the briefing in advance, and the company will address common concerns during the session [34][36]

Group 1 - The company has issued convertible bonds amounting to RMB 117,500 million, with a net amount of RMB 116,298.33 million after deducting issuance costs [4][15]. - The funds raised have been fully deposited into a special account established for this purpose, and the company has signed tripartite supervision agreements with relevant parties [5][6]. - As of June 30, 2025, the balance in the special account includes RMB 10,000 million in unexpired financial products [5][6]. Group 2 - The company has not experienced any significant changes in its operational situation during the reporting period [13]. - There have been no abnormal situations regarding the investment projects funded by the raised capital [7]. - The company has not used idle raised funds to temporarily supplement working capital during the first half of 2025 [9][10]. Group 3 - The company has approved the use of RMB 77,606.10 million of the raised funds to replace self-raised funds previously invested in projects and to cover issuance costs [8]. - The company has also approved the use of up to RMB 400 million of idle raised funds for cash management, with a balance of RMB 100 million utilized for this purpose as of June 30, 2025 [9][10]. - There are no instances of using excess raised funds for new projects or to repay bank loans during the reporting period [10][11]. Group 4 - The company has decided to cancel its supervisory board, transferring its responsibilities to the audit committee of the board of directors [24][45]. - The registered capital of the company has increased from RMB 113,834,777 to RMB 148,943,529 due to the completion of stock incentive plans and capital increases [25][48]. - The company has revised its articles of association to align with new regulatory requirements and improve corporate governance [49][50].

公司代码：603138 公司简称：海量数据 第一节 重要提示 1.1本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规 划，投资者应当到www.sse.com.cn网站仔细阅读半年度报告全文。 1.2本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 1.3董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无。 登录新浪财经APP 搜索【信披】查看更多考评等级 第二节 公司基本情况 2.1公司简介 ■ 2.2主要财务数据 单位：元 币种：人民币 ■ 2.3前10名股东持股情况表 单位: 股 ■ 2.4截至报告期末的优先股股东总数、前10名优先股股东情况表 □适用 √不适用 2025年半年度募集资金存放 2.5控股股东或实际控制人变更情况 □适用 √不适用 2.6在半年度报告批准报出日存续的债券情况 □适用 √不适用 第三节 重要事项 公司应当根据重要性原则，说明报告期内公司经营情况的重大变化，以及报告期内发生的对公司经营情 况有重大影响和预计未来会有重大影响的事项 □适用 √ ...

Fundraising Overview - The company has received approval from the China Securities Regulatory Commission to issue 86,546,026 A-shares at a price of 12.71 yuan per share, raising a total of approximately 1.1 billion yuan, with a net amount of about 1.09 billion yuan after deducting issuance costs [1][2] Fund Management and Supervision - A tripartite supervision agreement for the management of the raised funds has been signed with relevant financial institutions to ensure compliance with regulations and protect investor rights [1][3] - As of August 8, 2025, the balance in the dedicated account for the raised funds is approximately 1,094.15 million yuan, which is exclusively for the use of the funds raised from the A-share issuance [3][4] Responsibilities and Compliance - The company is required to comply with various laws and regulations regarding fund management and usage, and must maintain detailed records of all fund expenditures [4][5] - The sponsoring institution is responsible for supervising the use of the raised funds and must conduct regular checks on the dedicated account [4][6] Reporting and Accountability - The company must provide monthly account statements to the sponsoring institution and notify them of any significant withdrawals exceeding 20% of the net raised funds [5][6] - Failure to comply with the reporting requirements may result in the termination of the supervision agreement and the need to establish a new dedicated fund account [6]